At the news
? BEARISHIMPACT 5/10 8-K filed Nov 9, 2026 at 16:05 ET
Cash and securities totaled $461.6M, down from $582.7M at Q1 end, with cash runway into 2028. Key pipeline milestones include an FDA PDUFA date of April 28, 2027 for varegacestat, EMA MAA validation, and IND clearance for IM-1340.
- Net loss of $85.8M for Q3 2026, vs $57.5M in Q3 2025
- Cash, cash equivalents and marketable securities totaled $461.6M as of Sep 30, 2026
- R&D expenses rose to $69.5M from $49.2M year-over-year
- Varegacestat PDUFA target action date set for April 28, 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access